Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Oral vs IV Iron in Clinical Practice
Panelists discuss how oral iron therapy, although convenient and cost-effective, has significant limitations, including gastrointestinal adverse effects and poor absorption, leading many patients to experience iron intolerance or inadequate response, which often necessitates switching to intravenous iron administration for more reliable and rapid repletion of iron stores.
EP: 1.Background and Causes of Iron Deficiency Anemia
EP: 2.Pathophysiology of Iron Deficiency Anemia
EP: 3.Symptoms and Epidemiology of Iron Deficiency Anemia
EP: 4.Diagnosis and Common Comorbidities Seen With Iron Deficiency Anemia
EP: 5.Monitoring Patients With Iron Deficiency Anemia After Diagnosis
Now Viewing
EP: 6.Oral vs IV Iron in Clinical Practice
EP: 7.FDA-Approved IV Iron Formulations
EP: 8.Factoring in Safety Considerations With IV Iron Products
EP: 9.Adverse Effects Associated With Hypophosphatemia
EP: 10.Clinical Impact of Hypophosphatemia
EP: 11.Clinical and Economic Consequences of Nonadherence to IV Iron
EP: 12.Adherence and Time Spent Receiving IV Iron Infusions
EP: 13.Step Edits Associated with IV Iron Therapies
EP: 14.The Future of IV Iron Administration
EP: 15.Closing Thoughts on Iron Deficiency Anemia
Video content above is prompted by the following:
- What are the advantages and disadvantages of oral versus intravenous (IV) iron therapy in the treatment of IDA?
- Please define oral iron intolerance. What are the potential reasons and subsequent steps for patients with IDA who have had an unsatisfactory response to oral iron therapy?
Related Videos
Related Content
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Article
Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
